Skip to Main Content

Paper Details

Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> <sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Clin Cancer Res
9
2021
Author NameAffiliation
Matthieu Resche-RigonSaint Louis Hospital APHP
Matthieu Resche-RigonUniversite de Paris, INSERM U3, Saint Louis Hospital APHP
  • 1 - 2

Datasets

Release 1.2